MedTrace Logo

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

NCT01652560 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2012-07-30

No results posted yet for this study

Summary

\- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

Conditions

Interventions

DRUG

bevacizumab

The patients will be treated with Avastin combined neoadjuvant chemotherapy

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • LiNanlin,Ph.D, Chief Physician,Clinical Professor

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-06-30
Completion
2014-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01652560 on ClinicalTrials.gov